Eikon TherapeuticsEIKN
Recorded

Eikon Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Seamus FernandezAnalyst

Welcome to day two of Guggenheim's Healthcare Innovation Conference. Really pleased to be joined by Eikon Therapeutics. I'm Seamus Fernandez, one of the analysts here at Guggenheim. To my immediate left is Roger Perlmutter. Many of you know Roger from his days at Merck and at Amgen, prior to that, developing breakthrough therapies like Repatha at Amgen and a number of other therapies there. Uniquely, KEYTRUDA, which I believe is now the largest ever oncology product developed and a transformational immuno-oncology therapy. To his immediate left is Freddie Bowie, the CFO. Roger, I think this is just a great opportunity to dive in and talk a little bit more about what came out of ESMO.

Seamus FernandezAnalyst

I think I just kind of want to jump right into the clinical story of Eikon, because that's really what I think is uniquely exciting, where you've taken this platform and brought it to a number of unique therapeutics.

Roger PerlmutterChairman and CEO

Mm-hmm. Yeah, ESMO was an important meeting for us. We had seven abstracts at ESMO, which is a lot even for a large company, and certainly for a small company, an enormous number, spanning four major programs, each one of which had different aspects. For us, the meeting was an extraordinary opportunity to interact with key opinion leaders. There were 40,000 attendees at ESMO this year in Madrid. Key opinion leaders, of course, and also our clinical trialists. It's worth mentioning that Eikon, of course, a small biotech company, is kind of a big story. We have over 1,000 patients enrolled in various clinical trials, and we do all of this work ourselves. We do all of the clinical work ourselves. It's not done with a contract research organization. We have our own regulatory, safety, quality, biostats, clinical operations, clinical data management.

Roger PerlmutterChairman and CEO

The entire thing is done by us. We're busy, let's say it that way. The range of different advanced malignancies, because we focus on advanced malignancies, and our desire is to take people who are really quite ill and permit them to lead their lives for a much longer period of time. We are active in breast and prostate, in ovarian, in non-small cell lung cancer, in melanoma, in gastric, in colorectal, in endometrial, a huge range of different programs addressing important unmet medical needs for patients with advanced malignancy.

Seamus FernandezAnalyst

Yeah. Great. So, at ESMO, if there were the key datasets that you would highlight, we can kind of go through each of them individually.

Seamus FernandezAnalyst

Sure. Happy to. So, let's go through, first and foremost, your 001 asset, or EIK1001 asset, the TLR7/8 dual agonist.

Seamus FernandezAnalyst

Just in terms of the mechanism and the systemic dosing profile, what have we learned so far about this, and what's unique about this 7/8 opportunity?

Roger PerlmutterChairman and CEO

Right. Okay, so EIK1001 is a systemically administered dual agonist of Toll-like receptors seven and eight. To really put it in context, we have to step back for a minute and talk about checkpoint inhibitors.

Roger PerlmutterChairman and CEO

Yeah. Really, almost from the beginning, the observation, first of all, that checkpoint inhibition works was a big surprise.

Roger PerlmutterChairman and CEO

Because although immune surveillance as an idea, that is that one thing that your immune system does for you aside from the principal role of protection against infectious agents, of course some of those do cause malignancy, but infectious agents, is that they, as Macfarlane Burnet hypothesized many, many years ago, they are responsible for engaging in a surveillance activity and eliminating malignant cells. I have to be honest with you, that never made any sense to me. People who have immunodeficiency do not get solid tumors. That is not what happens.

Roger PerlmutterChairman and CEO

Yeah. There is not a lot of evidence, or there was not a lot of evidence that that mechanism was in play.

Roger PerlmutterChairman and CEO

The availability of checkpoint inhibitors, and from the very first time I saw what became pembrolizumab, now KEYTRUDA, the surprise was, of course, it is not a vaccine. It is not stimulating an immune response. It is revealing a preexisting immune response.

Roger PerlmutterChairman and CEO

Yeah. That is what it does.

Roger PerlmutterChairman and CEO

And the question almost immediately was, why does it not work in everyone? And the answer is, it works in a minority, unfortunately.

Roger PerlmutterChairman and CEO

Yeah. A minority of patients are responsive to checkpoint inhibitors.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day